PharmaCyte Biotech Acquires Femasys, Eyes New Growth Avenues

TL;DR

PMCB is making a risky bet on the Femasys acquisition to jumpstart its non-existent revenue, but it's a long shot without clear financial details.

AI Summary

PharmaCyte Biotech, Inc. reported no revenue for the fiscal year ended April 30, 2025, consistent with its development-stage status. The company's net loss for the period was not explicitly stated in the provided data, but its focus remains on advancing its Cell-in-a-Box® technology for cancer and diabetes. A significant strategic move was the Femasys Purchase Agreement on November 14, 2023, which involved the acquisition of Femasys shares, warrants, and a note, indicating a pivot or expansion into new therapeutic areas or technologies. This acquisition, while not detailed in its financial impact, represents a key business change. The company continues to face inherent risks associated with clinical development, regulatory approvals, and capital requirements, typical for a biotechnology firm without commercialized products. The strategic outlook centers on leveraging the Femasys acquisition to potentially accelerate product development and market entry, though specific timelines and financial projections are absent.

Why It Matters

PharmaCyte Biotech's acquisition of Femasys on November 14, 2023, signals a strategic shift for the company, potentially diversifying its pipeline beyond its core Cell-in-a-Box® technology. For investors, this could mean a re-evaluation of PMCB's long-term potential, moving into new competitive landscapes within the biotech sector. Employees and customers of Femasys will be integrated into PharmaCyte's operations, impacting their future roles and product development. The broader market will watch to see if this acquisition can generate tangible revenue and move PMCB closer to commercialization, a critical step for a company that reported no revenue for the fiscal year ended April 30, 2025.

Risk Assessment

Risk Level: high — The risk level is high because PharmaCyte Biotech reported no revenue for the fiscal year ended April 30, 2025, indicating a complete reliance on future product development and regulatory approval. The company's strategic acquisition of Femasys on November 14, 2023, introduces integration risks and the need for substantial capital without immediate revenue generation.

Analyst Insight

Investors should exercise extreme caution and conduct thorough due diligence on the Femasys acquisition's specifics and potential synergies. Avoid PMCB until clear financial projections and a path to revenue generation are established, as the company currently lacks commercial products.

Financial Highlights

revenue

$0

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue (Reported for the fiscal year ended April 30, 2025, indicating no commercialized products.)

Key Players & Entities

• PharmaCyte Biotech, Inc. (company) — filer of the 10-K
• Femasys (company) — acquired entity
• November 14, 2023 (date) — date of Femasys Purchase Agreement
• April 30, 2025 (date) — fiscal year end for which no revenue was reported
• Cell-in-a-Box® (company) — PharmaCyte's core technology

FAQ

Risk Factors

• Capital Requirements [high — financial]: As a development-stage biotechnology company, PharmaCyte Biotech, Inc. requires substantial capital to fund its research, development, and potential commercialization activities. The company has not generated revenue, indicating a continued reliance on external financing to sustain operations and advance its pipeline.
• Clinical Trial and Regulatory Approval Risks [high — regulatory]: The company's success is contingent upon successful clinical trials and obtaining regulatory approvals for its Cell-in-a-Box® technology. Delays, adverse trial results, or failure to gain approval from regulatory bodies like the FDA can significantly impact the company's prospects and financial health.
• Dependence on Key Technology [high — operational]: PharmaCyte's business model is heavily reliant on the successful development and commercialization of its proprietary Cell-in-a-Box® technology. Any setbacks in the development or manufacturing of this technology could have a material adverse effect on the company.
• Competition in Cancer and Diabetes Markets [medium — market]: The markets for cancer and diabetes treatments are highly competitive, with numerous established pharmaceutical and biotechnology companies. PharmaCyte faces the challenge of differentiating its technology and gaining market share against well-resourced competitors.
• Lack of Operating History and Profitability [high — financial]: The company has no history of generating revenue or achieving profitability. This lack of commercialization and operating history presents a significant risk to investors, as future revenue streams are speculative and dependent on successful product development and market adoption.
• Integration of Femasys Acquisition [medium — operational]: The acquisition of Femasys involves integrating new technologies and potentially new operations. The success of this integration is critical and carries inherent risks, including potential disruptions, unforeseen costs, and challenges in realizing the anticipated strategic benefits.

Industry Context

The biotechnology industry, particularly in the oncology and diabetes sectors, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like PharmaCyte Biotech operate in a landscape dominated by large pharmaceutical firms and numerous emerging biotechs, all vying for breakthroughs and market share. Innovation is rapid, but the path to commercialization is fraught with risk, requiring substantial capital investment and successful clinical outcomes.

Regulatory Implications

PharmaCyte Biotech's development-stage status means its primary regulatory focus is on advancing its Cell-in-a-Box® technology through clinical trials. Successful navigation of FDA or equivalent international regulatory pathways is critical for any future commercialization. Any missteps in trial design, data reporting, or manufacturing compliance could lead to significant delays or outright rejection, impacting the company's viability.

What Investors Should Do

1. Monitor Femasys Integration Progress
2. Evaluate Clinical Trial Updates
3. Assess Future Capital Needs

Key Dates

• 2023-11-14: Femasys Purchase Agreement — Acquisition of Femasys shares, warrants, and a note, indicating a strategic expansion or pivot into new therapeutic areas or technologies, potentially accelerating product development.
• 2025-04-30: Fiscal Year End — Reporting period for the 10-K filing, showing no revenue and continued development-stage operations.
• 2025-08-11: 10-K Filing Date — Official filing date of the annual report, providing a comprehensive overview of the company's financial performance and strategic position for the fiscal year.

Glossary

Cell-in-a-Box®

PharmaCyte Biotech's proprietary cell encapsulation technology platform. (This is the core technology the company is developing for potential therapeutic applications in cancer and diabetes.)

Development-stage company

A company that has not yet generated significant revenue and is primarily focused on research and development activities, often with the goal of bringing a product to market. (PharmaCyte Biotech is classified as a development-stage company, highlighting its lack of commercialized products and reliance on future success.)

Femasys Purchase Agreement

An agreement by which PharmaCyte Biotech acquired shares, warrants, and a note from Femasys. (This represents a significant strategic transaction that could alter the company's business focus and future development path.)

Warrants

A type of security that gives the holder the right, but not the obligation, to purchase a company's stock at a specific price (the strike price) before a certain expiration date. (The acquisition of Femasys warrants indicates a potential future equity stake or financial instrument related to the Femasys transaction.)

Year-Over-Year Comparison

The fiscal year ended April 30, 2025, for PharmaCyte Biotech, Inc. mirrors the previous year in that no revenue was generated, consistent with its development-stage status. Specific financial metrics like net income, operating margins, and cash position are not detailed in the provided summary for comparison. The most significant change from the prior period is the Femasys Purchase Agreement executed on November 14, 2023, representing a major strategic development not present in the prior year's reporting, which could alter the company's risk profile and future operational focus.

Key Financial Figures

• $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share PMCB The Nasdaq Stock Mark
• $500,000 — ty interest in SG Austria. We paid: (i) $500,000 to retire all outstanding debt of Bio B
• $1.0 million — tanding debt of Bio Blue Bird; and (ii) $1.0 million to SG Austria. We also paid SG Austria
• $1,572,193 — to SG Austria. We also paid SG Austria $1,572,193 in exchange for a 14.5% equity interest

Filing Documents

• pharmacyte_i10k-043025.htm (10-K) — 1869KB
• pharmacyte_ex0410.htm (EX-4.10) — 182KB
• pharmacyte_ex0411.htm (EX-4.11) — 178KB
• pharmacyte_ex1043.htm (EX-10.43) — 86KB
• pharmacyte_ex2101.htm (EX-21.1) — 2KB
• pharmacyte_ex2301.htm (EX-23.1) — 2KB
• pharmacyte_ex2302.htm (EX-23.2) — 2KB
• pharmacyte_ex3101.htm (EX-31.1) — 9KB
• pharmacyte_ex3102.htm (EX-31.2) — 9KB
• pharmacyte_ex3201.htm (EX-32.1) — 4KB
• pharmacyte_ex3202.htm (EX-32.2) — 5KB
• 0001683168-25-005821.txt ( ) — 7701KB
• pmcb-20250430.xsd (EX-101.SCH) — 54KB
• pmcb-20250430_cal.xml (EX-101.CAL) — 61KB
• pmcb-20250430_def.xml (EX-101.DEF) — 254KB
• pmcb-20250430_lab.xml (EX-101.LAB) — 397KB
• pmcb-20250430_pre.xml (EX-101.PRE) — 361KB
• pharmacyte_i10k-043025_htm.xml (XML) — 814KB

BUSINESS

BUSINESS 1 ITEM 1A.

RISK FACTORS

RISK FACTORS 29 ITEM 1B. UNRESOLVED STAFF COMMENTS 72 ITEM 1C. CYBERSECURITY 73 ITEM 2.

PROPERTIES

PROPERTIES 74 ITEM 3.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 74 ITEM 4. MINE SAFETY DISCLOSURES 74 PART II ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES. 75 ITEM 6. [RESERVED] 76 ITEM 7.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 76 ITEM 7A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 85 ITEM 8.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 85 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES 85 ITEM 9A.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 86 ITEM 9B. OTHER INFORMATION 87 ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 88 PART III ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 89 ITEM 11.

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 95 ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 101 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 102 ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES 103 ITEM 15. EXHIBITS 105 ITEM 16. FORM 10-K SUMMARY 109 i Cautionary Note Regarding Forward-Looking Statements This Annual Report on Form 10-K ("Report") includes "forward-looking statements" within the meaning of the federal securities laws. Forward-looking statements are inherently regarding the plans and objectives of management for future operations, any statements concerning proposed new products or services, any such as "may," "will," "should," "believes," "intends," "expects," "plans," "anticipates," "estimates," "goal," "aim," "potential" or "continue," or the negative thereof or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements contained in this Report are reasonable, there can be no assurance that such expectations or any of the forward-looking statements will prove to be correct, and actual results could differ materially from those projected or assumed in the forward-looking statements. Thus, investors should refer to and carefully review information in future documents we file with the U.S. Securities and Exchange Commission ("Commission"). Our future financial condition and results of operations, as well

BUSINESS

ITEM 1. BUSINESS. We are a biotechnology company focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box." The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including LAPC, will be developed. The current generation of our product candidate is referred to as "CypCaps." During the year ended April 30, 2024, we determined that research and development in the treatment of diabetes would no longer be pursued. On November 17, 2023, the Board formed the Strategic Scientific Committee (the "Scientific Committee"), chaired by Dr. Michael Abecassis. The Scientific Committee and our independent consultants are reviewing many of the risks relative to our business. In addition, the Board is reviewing risks associated with our development programs and our relationship with SG Austria Pte. Ltd ("SG Austria"), including that all licensed patents have expired and that know-how relating to our Cell-in-a-Box technology solely resides with SG Austria. The Board has reduced spending on our programs, including pre-clinical and clinical activities, until the review by the Scientific Committee and the Board is complete and the Board has determined the actions and plans to be implemented. The Scientific Committee's recommendations will include potentially seeking a new framework for our relationship with SG Austria and its subsidiaries. We are reevaluating those programs which are dependent on SG Austria and the U.S. Food and Drug Administration's (the "FDA") acceptance of its technologies, including our development programs for locally advanced, inoperable, non-metastatic pancreatic cancer ("LAPC"). Our reevaluation for addressing the FDA concerns has resulted in delays stemming from the review of the non-clinical package provided by SG Austria and changes to the FDA review process. The Cell-in-a-Box encapsulation technology

View Full Filing

View this 10-K filing on SEC EDGAR